[ad_1]
Biophytis SA (Euronext Growth Paris: ALBPS), (“Biophytis” or the “Company”), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today reports its financial results for the first half of 2024, and takes stock of the company’s main advances.
Stanislas Veillet, CEO of Biophytis, declares: “We are particularly satisfied with the progress made during this first half of 2024. The launch of our OBA clinical program in obesity, in response to a major public health problem, and our partnership with Blanver to develop BIO101 in Latin America, are key steps
which illustrate Biophytis’ ability to innovate and seize market opportunities.
We are now entering a crucial phase where the results of our clinical trials, particularly in the field of obesity, and the continuation of our partnership strategy with regional pharmaceutical laboratories, particularly in Asia, could radically transform the future of the company.
In financial markets which continue to be very difficult, the Company has been able to extend its bond financing line, and is actively working on recapitalization solutions allowing it to continue its development. »
[ad_2]
Source link -86